MNKD — MannKind Corporation stock price, charts and financials

QT50MannKind Corporation

MannKind Corporation (NASDAQ: MNKD) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
3.96
+0.16+4.21%
OverviewShort InterestFilings
MNKDQT50MannKind Corporation·NASDAQ
3.96+4.21%
Earnings
Up 4.2% — Reported earnings — EPS missed by 2150%, revenue missed by 14%.
High confidence
TA
Loading chart...
Signal & projected range
QT Score downgradeHistorical pattern — not a prediction
Range still being built for this setupWe don’t yet have a frozen historical track record for qt score downgrade to describe a reliable spread of outcomes. The projected range appears once its backtest is established.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
OCUL+2.26%$8.59STOK+7.14%$31.67TSHA+7.27%$6.20AUPH+2.47%$14.93MESO+2.28%$14.80URGN+3.45%$39.92TYRA+1.53%$32.53IOVA+0.93%$4.36
Snapshot
Index-P/E-EPS (ttm)-0.08Insider Own4.34%Shs Outstand308.95MPerf Week-3.80%
Market Cap1.17BForward P/E23.38EPS next Y0.16Insider Trans0.03%Shs Float302.90MPerf Month-15.93%
Enterprise Value1.48BPEG-EPS next Q-Inst Own-Short Float9.31%Perf Quarter33.80%
Income-24.00MP/S3.25EPS this Y106.25%Inst Trans-Short Ratio4.96Perf Half Y-34.26%
Sales361.00MP/B-EPS next Y3150.00%ROA-3.21%Short Interest28.19MPerf YTD-32.98%
Book/sh-0.19P/C8.76EPS next 5Y213.29%ROE45.59%52W High6.78 -41.63%Perf Year0.53%
Cash/sh0.43P/FCF94.98EPS past 3/5Y-ROIC1.80%52W Low2.32 70.40%Perf 3Y-14.03%
Dividend Est.-EV/EBITDA54.70Sales past 3/5Y51.68% 39.95%Gross Margin75.96%Volatility5.10% 5.42%Perf 5Y-13.24%
Dividend TTM-EV/Sales4.09EPS Y/Y TTM-182.30%Oper. Margin3.71%ATR (14)0.23Perf 10Y-23.86%
Dividend Ex-Date-Quick Ratio1.50Sales Y/Y TTM26.22%Profit Margin-6.63%RSI (14)45.51Recom2.85
Dividend Gr. 3/5Y-Current Ratio1.87EPS Q/Q-SMA20-5.24%Beta1.10Target Price9.25
Payout0.00%Debt/Eq1.63Sales Q/Q15.38%SMA50-1.77%Rel Volume0.89Prev Close3.80
Employees592LT Debt/Eq-8.31EarningsAug 05SMA200-12.17%Avg Volume5.87MPrice3.96
IPO DateJul 28, 2004Option/ShortYes / YesEPS/Sales Surpr.-2150.22% -14.43%Net Debt/EBITDA13.93Volume5,251,007Change4.21%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-30-26ReiteratedWells FargoOverweight$11 → $14
Jun-01-26ReiteratedWells FargoOverweight$10 → $11
May-07-26ReiteratedWells FargoOverweight$10
May-07-26ReiteratedMizuhoOutperform$8.00 → $7.00
May-07-26ReiteratedHC Wainwright & Co.Buy$11 → $10
Apr-13-26ReiteratedMizuhoOutperform$8.00
Apr-08-26ReiteratedTruist Financial$7.00 → $6.00
Feb-27-26DowngradeRBC CapitalOutperform → Sector Perform
Nov-24-25InitiatedTruistBuy$9.00
Sep-02-25ReiteratedHC Wainwright & Co.Buy$9.00 → $11
Latest News
Jul-31-26
Jul-31-2607:03PM
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload - SlideshowSeekingAlpha
Jul-30-26
Jul-30-2602:24PM
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcriptseekingalpha.com
Jul-29-26
Jul-29-2607:04PM
MannKind's Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underwaymarketbeat.com
07:02AM
MannKind injection helps heart failure patients avoid ER infusionsreuters.com
06:30AM
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPFglobenewswire.com
Jul-28-26
Jul-28-2604:01PM
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026globenewswire.com
Jul-26-26
Jul-26-2602:02AM
MannKind (NASDAQ:MNKD) Shares Gap Up – Still a Buy?defenseworld.net
Jul-24-26
Jul-24-2602:06PM
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Diseasebenzinga.com
12:01PM
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload TranscriptSeekingAlpha
11:05AM
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPEmarketbeat.com
06:35AM
MannKind Announces $50 Million Private Placementglobenewswire.com
06:30AM
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Diseaseglobenewswire.com
Jul-20-26
Jul-20-2607:24PM
What This MannKind Filing Reveals About Three Years of Underperformancefool.com
07:16PM
What This MannKind Director Sale Signals With $32.7 Million in Quarterly Royalties Revenue Potentially at Riskfool.com
07:05PM
What This MannKind Sale Signals With Tyvaso Royalties at $32.7 Millionfool.com
Company

MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue36134928619910075656328
Cost of Goods Sold Incl. D&A876177635739252820
Gross Profit274288209136423741357
Selling, General and Administrative Excl. Other17314494949177597580
Research and Development736646312012679
Other Operating Expense1539-43-5-523-2-1
Operating Income1339739-64-47-48-45-77
Interest Expense3814382525179119
Unusual Expense
—————————
Non-Operating Income (Expense)-3-24-461-1704-1
Net Income Before Taxes-28131-10-87-81-57-52-87
Income Taxes-5-43200000
Consolidated Net Income-24628-12-87-81-57-52-87
Net Income From Continuing Operations-24628-12-87-81-57-52-87
Net Income-24628-12-87-81-57-52-87
EPS (Recurring)-0.080.020.10-0.04-0.44-0.37-0.26-0.31-0.60
EPS (Basic, Before Extraordinaries)-0.080.020.10-0.04-0.44-0.37-0.26-0.31-0.60
EPS (Diluted)-0.080.020.10-0.04-0.44-0.37-0.26-0.31-0.60
EBITDA27287715-56-61-45-39-76
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio—283.5066.15——————
Price To Sales Ratio3.384.976.164.8813.5414.5110.744.015.45
Gross Margin75.9082.5273.0868.3442.0049.3363.0855.5625.00
Operating Margin3.6011.1725.524.52-64.00-62.67-73.85-71.43-275.00
Net Margin-6.651.729.79-6.03-87.00-108.00-87.69-82.54-310.71
Shares Outstanding308306274267257249223196144
Market Capitalization1,2201,7351,7629721,3541,088698253153
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$6.80$5.52$4.25$2.97$1.69● Close Price0.00M0.49M0.97M1.46M1.95MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thomson DavidEVP Genl Counsel & SecretaryJul 17 '26Sale4.0524,10997,641797,554Jul 17
Binder Steven B.DirectorJul 17 '26Sale4.0652,485213,089824,918Jul 17
Castagna MichaelChief Executive OfficerJul 15 '26Option Exercise0.00350,26002,796,979Jul 17
Tross Stuart AChief People & Workpl OfficerJul 15 '26Option Exercise0.0093,79001,123,950Jul 17
Singh Sanjay REVP Technical OperationsJul 15 '26Option Exercise0.0070,5500525,761Jul 17
Thomson DavidEVP Genl Counsel & SecretaryJul 15 '26Option Exercise0.0093,7900920,089Jul 17
Binder Steven B.DirectorJul 15 '26Option Exercise0.0093,7900901,798Jul 17
Binder Steven B.DirectorMay 12 '26Sale3.2916,94055,733808,008May 13
Thomson DavidEVP Genl Counsel & SecretaryMay 12 '26Sale3.293,0339,979826,299May 13
Castagna MichaelChief Executive OfficerMar 10 '26Buy2.59100,000259,0002,575,911Mar 10
Tross Stuart AChief People & Workpl OfficerJan 08 '26Sale6.3347,006297,548985,007Jan 09
Castagna MichaelChief Executive OfficerDec 17 '25Option Exercise4.55115,804526,9082,570,596Dec 19
Castagna MichaelChief Executive OfficerDec 17 '25Sale6.0165,804395,4822,504,792Dec 19
Castagna MichaelChief Executive OfficerDec 16 '25Option Exercise4.5521,31096,9612,526,102Dec 16
Castagna MichaelChief Executive OfficerDec 16 '25Sale6.0021,310127,8602,504,792Dec 16
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.